Alnylam’s longer-term RNAi treatment lowers blood pressure in mid-stage study
One to two doses of an RNA interference treatment developed by Alnylam Pharmaceuticals reduced blood pressure for six months in a mid-stage clinical trial, according to new research presented this weekend at a medical meeting.
Alnylam’s goal is to develop the treatment, zilebesiran, into an add-on or alternative to current blood pressure medications, which are meant to be taken every day. The company previously shared in September that the study had met its primary goal, and this weekend’s results offered new details.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
